These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 38863635)

  • 1. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
    Liu F; Miao X; Han L; Song X
    Front Oncol; 2024; 14():1390006. PubMed ID: 38863635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
    Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J
    MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-NK cells: a promising cellular immunotherapy in lymphoma.
    Khanmohammadi S; Rezaei N
    Expert Opin Biol Ther; 2023 Jan; 23(1):37-47. PubMed ID: 36453808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
    Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
    Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-NK cells for cancer immunotherapy: from bench to bedside.
    Zhang L; Meng Y; Feng X; Han Z
    Biomark Res; 2022 Mar; 10(1):12. PubMed ID: 35303962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
    Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
    Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
    Wang X; Yang X; Yuan X; Wang W; Wang Y
    Exp Hematol Oncol; 2022 Nov; 11(1):85. PubMed ID: 36324149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor engineered natural killer cells for cancer therapy.
    Zhang Y; Zhou W; Yang J; Yang J; Wang W
    Exp Hematol Oncol; 2023 Aug; 12(1):70. PubMed ID: 37563648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions.
    Zhong Y; Liu J
    Cell Death Discov; 2024 Jul; 10(1):318. PubMed ID: 38987565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.
    Włodarczyk M; Pyrzynska B
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response.
    Cienfuegos-Jimenez O; Vazquez-Garza E; Rojas-Martinez A
    Curr Gene Ther; 2022; 22(4):303-318. PubMed ID: 34923939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Progress of CAR-NK Therapy in Cancer Treatment.
    Pang Z; Wang Z; Li F; Feng C; Mu X
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.